This precision therapy, recently authorized by the Ministry of Health, targets cancer cells directly through intravenous administration. The method destroys tumors while preserving surrounding healthy tissue, marking a significant step in treating one of the leading causes of cancer death in men over 50.

Administered at the Nuclear Medicine department, the treatment consists of six sessions over nine months. It is designed for patients who have already undergone hormone therapy and chemotherapy and meet specific health criteria regarding kidney and liver function.

The first patient treated in Badalona is a 65-year-old man with bone and lymph node metastasis. Clinical trials, including contributions from Bellvitge University Hospital, show the therapy can reduce tumor size by 40% and significantly extend life expectancy.